Published in Vaccine Weekly, May 6th, 2009
The phase-1 clinical trial, which is under way at both Stanford and Vanderbilt University in Nashville, Tenn., aims to test the safety of and immune response to different doses of the vaccine in a total of 72 healthy adults. It is funded by the National Institutes of Health.
Results from this study will allow a second trial to begin in Africa this year.
“This a chance for those who know that malaria causes millions of deaths every year to step forward and help in the search for...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly